Krystal Biotech (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded up $12.17 during trading on Friday, hitting $234.13. The stock had a trading volume of 537,880 shares, compared to its average volume of 326,125. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $234.65. The firm has a market cap of $6.79 billion, a P/E ratio of 35.10 and a beta of 0.48. The business has a fifty day moving average of $197.92 and a two-hundred day moving average of $162.51.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million for the quarter, compared to analysts’ expectations of $93.72 million. As a group, research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Institutional Investors Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D grew its stake in shares of Krystal Biotech by 45.2% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after purchasing an additional 4,682 shares during the period. EP Wealth Advisors LLC acquired a new stake in Krystal Biotech during the first quarter worth about $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after purchasing an additional 365,304 shares during the last quarter. Edgestream Partners L.P. purchased a new stake in Krystal Biotech in the second quarter valued at approximately $2,705,000. Finally, S Squared Technology LLC boosted its stake in shares of Krystal Biotech by 2.1% in the first quarter. S Squared Technology LLC now owns 97,215 shares of the company’s stock valued at $17,528,000 after purchasing an additional 2,000 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday. Chardan Capital upped their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Bank of America raised their price objective on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Guggenheim set a $224.00 price objective on Krystal Biotech and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, HC Wainwright restated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Monday, September 15th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $228.14.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).